Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-11
DOI
10.1007/s12325-022-02423-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions
- (2020) Sandra Lopes et al. PHARMACOECONOMICS
- Obesity Prevalence in the Long-Term Future in 18 European Countries and in the USA
- (2020) Fanny Janssen et al. Obesity Facts
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
- (2014) R Ara et al. HEALTH TECHNOLOGY ASSESSMENT
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
- (2013) A. J. Hayes et al. DIABETOLOGIA
- The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England
- (2009) F. Søltoft et al. QUALITY OF LIFE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started